FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. 20549 |
|-------------|------------|
|-------------|------------|

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name ar <u>Hahn N</u> | | 2. Issuer Name and Ticker or Trading Symbol Verona Pharma plc [VRNA] | | | | | | | | | Chec | k all app Direc | ionship of Reportir all applicable) Director Officer (give title | | 10% O | | | | | |
|--|---|---|-------|----------------------------|---|--|---|--|-------------------|---|-------------------------------------|--------------------|---|---|--|---|--|---|--|--|
| (Last) (First) (Middle) 3 MORE LONDON RIVERSIDE | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 11/01/2021 | | | | | | | | | X | below) Chief Finar | | ncial | below) | Specify |
| (Street) LONDO (City) | NDON X0 SE1 2RE | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye | | | | ear) E | 2A. Deemed Execution Date, if any (Month/Day/Year) | | , | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A Disposed Of (D) (Instr. 3, | | | 5) | 5. Amount of Securities Beneficially Owned Following Reported | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | | | Code | v | Amount | | (A) or (D) | Price | | Transaction(s) (Instr. 3 and 4) | | | | (111341.4) |
| Ordinary Shares ⁽¹⁾ 11/01 | | | | | .1 | | | | F ⁽²⁾ | | 454,848 | 3 | D | \$0.64 | J ⁽³⁾ | 16,001,536 | | | D | |
| Ordinary Shares ⁽¹⁾ 11/02/2 | | | | | .1 | | | | S ⁽⁴⁾ | | 10,416 | | D | \$0.645 | 3 ⁽⁵⁾ | 15,991,120 ⁽⁶⁾ | | | D | |
| | | Tal | ble I | II - Derivati (e.g., pu | | | | | | | | | | | | Owne | d | | | |
| 1. Title of Derivative Security (Instr. 3) | ative Conversion Date rity or Exercise (Month/Day/Year) if any Conversion Date | | | | | ansaction of Derivat Securit Acquire (A) or Dispos of (D) (Instr. 3 and 5) | | rative rities ired r osed) : 3, 4 | Exp (Mo | iration | ercisable and I Date Iy/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4) | | De | Price of rivative curity str. 5) | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | Owr Fori Dire or Ir (I) (I | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | | Code | ode V (A) (D) | | | Date Exercisab | | Expiration Date | | Title | Number of Shares | | | | | | |

Explanation of Responses:

- 1. Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- 2. Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
- 3. The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 29, 2021 divided by eight (8).
- 4. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.
- 5. The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from \$0.6375 to \$0.66. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 5.
- 6. Consists of (i) 10,429,712 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,303,714 ADSs); and (ii) 5,561,408 Ordinary Shares underlying 695,176 ADSs.

/s/ Claire Poll, Attorney-infact for Mark Hahn

11/03/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.